Anixa Covid News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article
Share this article
HALLE (SAALE), Germany, May 7, 2021 /PRNewswire/  OntoChem GmbH, a German Life Science IT company, announced today that it has assigned its drug discovery technologies and assets, including its drug discovery collaboration with Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, to the newly formed MolGenie GmbH, a biotech company focusing on drug discovery and development.  
Anixa and OntoChem were seeking to develop an orally administrable, metabolically stable, non-toxic anti-viral therapy against SARS-CoV-2, the virus that causes Covid-19.  The partners had recently completed
in vitro antiviral cell-based studies and ....

Lutz Weber , Mike Catelani , Felix Berthelmann , Anixa Covid , Ontochem Gmb , Anixa Biosciences , Amit Kumar , Molgenie Gmb , Anixa Biosciences Inc , Ontochem Gmbh , German Life Science , Molgenie Gmbh , Syrian Hamster , Looking Statements , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Current Reports , லூட்ஸ் வெபர் , அமித் குமார் , சிரிய வெள்ளெலி , பார்க்கிறது அறிக்கைகள் , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் , ஆண்டு அறிக்கை , காலாண்டு அறிக்கைகள் , தற்போதைய அறிக்கைகள் ,